Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by husk16on Jul 12, 2013 11:29pm

77 Views

Post# 21605620

RE:RE:Publication timeline?

Thanks SanFran and BDA. The story is not over yet at all. If you are a believer the current SP could be a real gift.

RVX will be fine IF: they can show plaque regression (either for all patients or certain groups)
and/or Show Apoa1 trends across all studies, and/or Show HDL trends across studies.

I think even without Plaque Regression there will be a market for 208.

Apoa1 helps the heart, alzheimer's, diabetes, and possibly cancer.
HDL also is very beneficial.

IMO 208 will eventually be used by Big Pharma as a version 2.0 for their own drug. The buyout/license/royalty I have no idea right now.

Bullboard Posts

Rich TV Live's Stocks to Watch this week (May 31, 2024)